Rezolute (RZLT) · ersodetug
Date changed · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: before the end of 2026
We anticipate completing enrollment and announcing topline results from the study before the end of 2026.
· filed · SEC filing
After
Stated timing: mid-December 2026
REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026.
· filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/RZLT-ersodetug-2026-10-14, data as of Oct 18, 2026
https://www.orionbiotechai.com/changes/RZLT-ersodetug-2026-10-14
Rezolute (RZLT) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-K is a company’s annual report to the SEC, with audited financial statements.A Form 8-K is a report a company files with the SEC to announce a significant event between its regular reports.